---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-18T20:51:05.091985'
end_time: '2026-01-18T20:55:23.817392'
duration_seconds: 258.73
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: TARDBP
  gene_symbol: TARDBP
  uniprot_accession: Q13148
  protein_description: 'RecName: Full=TAR DNA-binding protein 43 {ECO:0000303|PubMed:7745706};
    Short=TDP-43 {ECO:0000303|PubMed:7745706};'
  gene_info: Name=TARDBP {ECO:0000303|PubMed:18396105, ECO:0000312|HGNC:HGNC:11571};
    Synonyms=TDP43 {ECO:0000303|PubMed:7745706};
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: Nucleotide-bd_a/b_plait_sf. (IPR012677); RBD_domain_sf. (IPR035979);
    RRM_dom. (IPR000504); TDP-43_C. (IPR049124); TDP-43_N. (IPR041105)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 18
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q13148
- **Protein Description:** RecName: Full=TAR DNA-binding protein 43 {ECO:0000303|PubMed:7745706}; Short=TDP-43 {ECO:0000303|PubMed:7745706};
- **Gene Information:** Name=TARDBP {ECO:0000303|PubMed:18396105, ECO:0000312|HGNC:HGNC:11571}; Synonyms=TDP43 {ECO:0000303|PubMed:7745706};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** Nucleotide-bd_a/b_plait_sf. (IPR012677); RBD_domain_sf. (IPR035979); RRM_dom. (IPR000504); TDP-43_C. (IPR049124); TDP-43_N. (IPR041105)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TARDBP" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TARDBP' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TARDBP** (gene ID: TARDBP, UniProt: Q13148) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q13148
- **Protein Description:** RecName: Full=TAR DNA-binding protein 43 {ECO:0000303|PubMed:7745706}; Short=TDP-43 {ECO:0000303|PubMed:7745706};
- **Gene Information:** Name=TARDBP {ECO:0000303|PubMed:18396105, ECO:0000312|HGNC:HGNC:11571}; Synonyms=TDP43 {ECO:0000303|PubMed:7745706};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** Nucleotide-bd_a/b_plait_sf. (IPR012677); RBD_domain_sf. (IPR035979); RRM_dom. (IPR000504); TDP-43_C. (IPR049124); TDP-43_N. (IPR041105)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TARDBP" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TARDBP' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TARDBP** (gene ID: TARDBP, UniProt: Q13148) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan and verification
We verified the identity of the target as human TARDBP (UniProt Q13148), encoding TAR DNA-binding protein 43 (TDP-43), a 414-amino-acid RNA/DNA-binding hnRNP with an N-terminal domain containing a bipartite nuclear localization signal (NLS), two RNA-recognition motifs (RRM1/RRM2), and a glycine-rich, low-complexity C-terminal domain (LCD). TDP-43 is predominantly nuclear but shuttles to the cytoplasm and localizes to stress granules; it binds UG-rich RNA and TG-rich ssDNA and is dosage-sensitive and essential. These features match the UniProt context and recent literature (casiraghi2024aggregationmechanismsof pages 10-14, lepine2024theeffectsof pages 54-58, part2024exploringtherole pages 26-30, riemenschneider2024exploringcellulartoxicity pages 24-27).

1) Key concepts and definitions
- Gene/protein: TARDBP (chromosome 1p36.22) encodes TDP-43, a ubiquitous RNA-binding protein central to RNA metabolism. Domain architecture: NTD with bipartite NLS (~aa 82–98), RRM1/RRM2 for nucleic acid binding, and a prion-like LCD/CTD harboring most ALS/FTD mutations and driving phase separation and aggregation (casiraghi2024aggregationmechanismsof pages 10-14, lepine2024theeffectsof pages 54-58, part2024exploringtherole pages 26-30, riemenschneider2024exploringcellulartoxicity pages 24-27).
- Nucleic-acid specificity: TDP-43 preferentially binds UGn-enriched RNAs and TG-rich ssDNA, engaging numerous pre-mRNAs and noncoding RNAs (casiraghi2024aggregationmechanismsof pages 10-14, lepine2024theeffectsof pages 54-58).
- Primary molecular functions: repression of cryptic exon inclusion and alternative splicing; regulation of mRNA stability and transport (including axonal); participation in miRNA biogenesis; autoregulation by binding its own 3′UTR to adjust TARDBP mRNA levels (casiraghi2024aggregationmechanismsof pages 10-14, lepine2024theeffectsof pages 54-58, part2024exploringtherole pages 26-30).
- Localization: predominantly nuclear; nucleocytoplasmic shuttling via NLS and reported NES; recruitment to stress granules and other RNP condensates under stress; nuclear TDP-43 condensation supports function (lepine2024theeffectsof pages 54-58, part2024exploringtherole pages 26-30).

2) Recent developments and latest research (prioritized 2023–2024)
- Pathogenesis scope: TDP-43 proteinopathy—nuclear depletion with cytoplasmic mislocalization and aggregation—is present in ~95–97% of ALS cases and ~45–>50% of FTLD cases, implicating combined loss- and gain-of-function mechanisms (Sep 4, 2023; Neural Regeneration Research; https://doi.org/10.4103/1673-5374.382233) (wang2024thepathogenicmechanism pages 1-1). 2024 reviews further synthesize mechanisms spanning nucleocytoplasmic transport, RNA metabolism, stress granules/LLPS, mitochondrial/ER dysfunction, proteostasis, and DNA damage responses (2024; dissertations/reviews) (riemenschneider2024exploringcellulartoxicity pages 24-27).
- LLPS/aggregation and oligomerization: N-terminal oligomerization supports splicing and LLPS; monomerization predisposes to pathology, linking early conformational states to disease (Science Advances, Aug 2023; https://doi.org/10.1126/sciadv.adf6895) (not in context ids). Reviews in 2024 detail LLPS control by domains and RNA (riemenschneider2024exploringcellulartoxicity pages 24-27).
- Autoregulation and dosage: TDP-43 tightly autoregulates via 3′UTR binding; shortened cytosolic isoforms (sTDP-43) arise as byproducts of autoregulation and are normally cleared by NMD and post-translational degradation; overexpression or escape from surveillance can be toxic (bioRxiv, Jul 2, 2024; https://doi.org/10.1101/2024.07.02.601776) (wang2024thepathogenicmechanism pages 1-1, lepine2024theeffectsof pages 54-58).
- RNA chaperone therapeutics: Short UG-containing RNAs can chaperone TDP-43 into soluble, import-competent conformers in cells and mouse models, improving phenotypes, whereas pure UG-repeats can disrupt function; motif design is critical (bioRxiv, Dec 14, 2024; https://doi.org/10.1101/2024.12.14.628507) (copley2024shortrnachaperones pages 15-17).
- Small-molecule-guided transcriptome correction: Connectivity Map-guided screen in TDP-43 mutant iPSC motor neurons identified MLN4924 (NAE inhibitor) as restoring viability and activity, implicating NEDDylation pathways (Scientific Reports preprint, Dec 2024; https://doi.org/10.21203/rs.3.rs-5404388/v1) (lepine2024transcriptomebasedscreeningin pages 49-54).

3) Current applications and real-world implementations
- Biomarkers: Neurofilament light (NfL) is widely used as a fluid biomarker reflecting axonal injury in ALS/FTD though not specific to TDP-43; pathological TDP-43 species in tissue remain a post-mortem diagnostic gold standard (2024) (part2024exploringtherole pages 26-30).
- RNA therapeutics: ASO strategies correcting cryptic splicing downstream of TDP-43 loss-of-function (e.g., STMN2 and UNC13A) are a leading translational direction; platform learnings from SOD1-ASO approvals inform TDP-43–centric programs (2023–2024 reviews cited within the context) (wang2024thepathogenicmechanism pages 1-1, lepine2024transcriptomebasedscreeningin pages 49-54).
- Experimental RNA chaperones: Short RNAs designed to bind RRMs can mitigate aggregation and improve motor neuron outcomes in preclinical models, suggesting a feasible modality akin to ASOs (Dec 2024) (copley2024shortrnachaperones pages 15-17).

4) Expert opinions and analyses
- Recent reviews emphasize that TDP-43’s disease contribution integrates loss-of-function (cryptic exon derepression and splicing failure) with toxic gain-of-function (cytoplasmic condensates/aggregates), and that perturbations in nucleocytoplasmic transport, SG dynamics/LLPS, mitochondrial and ER-Golgi homeostasis intersect with RNA metabolism defects (Sep 2023; Neural Regeneration Research; 2024 dissertations/reviews) (wang2024thepathogenicmechanism pages 1-1, riemenschneider2024exploringcellulartoxicity pages 24-27).

5) Relevant statistics and data
- Prevalence in ALS: TDP-43 pathology in ~95–97% of ALS autopsies; familial ALS 5–10% of total; TARDBP mutations contribute ~4% of fALS, <1% of sALS (Sep 2023; Neural Regeneration Research; https://doi.org/10.4103/1673-5374.382233) (wang2024thepathogenicmechanism pages 1-1).
- Structural mutation distribution: Most ALS/FTD-linked TARDBP missense mutations map to the glycine-rich CTD/LCD, consistent with LLPS/aggregation roles (2024) (casiraghi2024aggregationmechanismsof pages 10-14, part2024exploringtherole pages 26-30).

Detailed functional annotation of TDP-43
- Binding specificity and targets: TDP-43 binds UGn-rich motifs across pre-mRNAs and ncRNAs; it represses cryptic exon inclusion in transcripts such as STMN2 and UNC13A, and regulates POLDIP3 and many neuronal RNAs implicated in axonal health (2024) (casiraghi2024aggregationmechanismsof pages 10-14, lepine2024theeffectsof pages 54-58).
- Autoregulation: TDP-43 binds a conserved region in its 3′UTR (TDPBR) to downregulate its own mRNA; dosage sensitivity is reinforced by NMD of shortened transcripts and rapid degradation of truncated protein products (Jul 2024) (lepine2024theeffectsof pages 54-58, wang2024thepathogenicmechanism pages 1-1).
- Subcellular localization and trafficking: Nuclear predominance via NLS; shuttling to cytoplasm under stress; incorporation into stress granules and other condensates. Nuclear condensation is linked to function; chronic stress/defective resolution predisposes to cytoplasmic aggregation (2024) (lepine2024theeffectsof pages 54-58, part2024exploringtherole pages 26-30, riemenschneider2024exploringcellulartoxicity pages 24-27).
- Phase separation/aggregation: LLPS is driven by multivalent RNA interactions (RRMs) and LCD interactions; persistent droplets can mature to less dynamic gels/solids. NTD oligomerization is essential for normal function; destabilization/monomerization increases aggregation propensity (2023–2024) (riemenschneider2024exploringcellulartoxicity pages 24-27).
- Post-translational modifications (PTMs): Pathological inclusions contain hyperphosphorylated (S409/S410 and S403/S404), ubiquitinated, and C-terminally cleaved TDP-43; SUMOylation and acetylation have been reported, and PTMs modulate LLPS and aggregation dynamics (2024) (part2024exploringtherole pages 26-30).

Pathways and cellular processes
- RNA surveillance and UPF1/NMD: TDP-43 interfaces with RNA surveillance and NMD; TDP-43 dysfunction perturbs UPF1-dependent RNA metabolism and alternative polyadenylation in disease models (2024 overview and related sources within context) (wang2024thepathogenicmechanism pages 1-1).
- Autophagy/UPS: Proteostasis pathways (ubiquitin–proteasome and autophagy) are consistently implicated in handling TDP-43 and its fragments; dysregulation contributes to accumulation and toxicity (2024) (wang2024thepathogenicmechanism pages 1-1, part2024exploringtherole pages 26-30).
- DNA damage response and nuclear bodies: TDP-43 interacts with lncRNA NEAT1 and paraspeckle biology; nuclear condensate homeostasis and DNA repair pathways are increasingly linked to TDP-43 function and dysfunction (2024 context) (riemenschneider2024exploringcellulartoxicity pages 24-27).
- Organelle trafficking: Mitochondrial and ER/secretory pathway disturbances co-occur with TDP-43 pathology; stress granule persistence and defective clearance connect to neurite/axonal transport defects (2023–2024 reviews) (wang2024thepathogenicmechanism pages 1-1, riemenschneider2024exploringcellulartoxicity pages 24-27).

Disease associations and clinical context
- ALS/FTD: Central to ALS (~95–97% pathology) and a major subset of FTLD; both wild-type and mutant TDP-43 contribute. TARDBP mutations are relatively rare causes but highlight critical structure–function links (wang2024thepathogenicmechanism pages 1-1, lepine2024transcriptomebasedscreeningin pages 49-54).
- LATE and AD co-pathology: TDP-43 proteinopathy appears in limbic-predominant age-related TDP-43 encephalopathy (LATE) and frequently co-occurs with AD, compounding neurotoxicity (2024 overview) (part2024exploringtherole pages 26-30, wang2024thepathogenicmechanism pages 1-1).

Therapeutic directions under active investigation
- ASOs restoring downstream targets: Strategies restoring STMN2 and other critical transcripts misprocessed upon TDP-43 loss-of-function are advancing preclinically (2023–2024 reviews summarized in context) (wang2024thepathogenicmechanism pages 1-1).
- Precision expression systems: Conceptual platforms exploit TDP-43 loss-of-function–triggered cryptic splicing to gate therapeutic expression selectively in diseased neurons (“TDP-REG”-like approaches), aligning with the principle of disease-restricted activation (2024 concept referenced in overviews) (wang2024thepathogenicmechanism pages 1-1).
- RNA chaperone/oligonucleotide binders: Carefully designed GU-rich RNAs (non–pure GU repeats) that bind RRMs can keep TDP-43 soluble and nuclear without impairing cryptic exon repression, showing efficacy in cell and mouse models (Dec 2024; bioRxiv) (copley2024shortrnachaperones pages 15-17).
- Small molecules: Pathway-guided screens (e.g., MLN4924) and proteostasis modulators are being explored to rebalance TDP-43 homeostasis (Dec 2024) (lepine2024transcriptomebasedscreeningin pages 49-54).
- Antibodies and immunotherapies: Considered for extracellular/propagating species or to modulate intracellular pools, but translational hurdles remain (2024 review perspective) (riemenschneider2024exploringcellulartoxicity pages 24-27).

Conclusion
Human TARDBP/TDP-43 (UniProt Q13148) is a dosage-sensitive, essential RBP with well-defined domains and UG-rich RNA specificity, orchestrating splicing repression (including cryptic exon suppression), mRNA stability/transport, and tight autoregulation via its 3′UTR. It is predominantly nuclear and undergoes regulated nucleocytoplasmic shuttling and LLPS; disease involves nuclear loss with cytoplasmic aggregation harboring hallmark PTMs. TDP-43 proteinopathy is nearly universal in ALS and prevalent in FTLD and aging-related TDP-43 encephalopathy, with multisystem cellular disturbances converging on RNA metabolism, proteostasis, organelle function, and nuclear body dynamics. 2023–2024 work refines early pathogenic steps (oligomerization/monomerization balance, nuclear condensation), expands links to RNA surveillance and organelle traffic, and advances oligonucleotide-based modalities (ASOs and RNA chaperones) and small-molecule strategies toward restoring TDP-43 homeostasis and downstream transcript integrity (casiraghi2024aggregationmechanismsof pages 10-14, lepine2024theeffectsof pages 54-58, lepine2024transcriptomebasedscreeningin pages 49-54, wang2024thepathogenicmechanism pages 1-1, part2024exploringtherole pages 26-30, riemenschneider2024exploringcellulartoxicity pages 24-27, copley2024shortrnachaperones pages 15-17, lepine2024theeffectsof pages 49-54).

References

1. (casiraghi2024aggregationmechanismsof pages 10-14): V Casiraghi. Aggregation mechanisms of tdp-43 protein in response to stress in amyotrophic lateral sclerosis and therapeutic approaches. Unknown journal, 2024.

2. (lepine2024theeffectsof pages 54-58): S Lépine. The effects of tardbp mutations associated with amyotrophic lateral sclerosis in human motor neurons derived from induced pluripotent stem cells. Unknown journal, 2024.

3. (part2024exploringtherole pages 26-30): Caroline Part. Exploring the role of endogenous tdp-43 sumoylation in mice: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Text, Feb 2024. URL: https://doi.org/10.20381/ruor-30175, doi:10.20381/ruor-30175. This article has 0 citations and is from a peer-reviewed journal.

4. (riemenschneider2024exploringcellulartoxicity pages 24-27): Henrick Riemenschneider. Exploring cellular toxicity mechanisms and immunotherapeutic potential of tdp-43 in als/ftd. Dissertation, Jan 2024. URL: https://doi.org/10.5282/edoc.34109, doi:10.5282/edoc.34109. This article has 0 citations.

5. (wang2024thepathogenicmechanism pages 1-1): Xinxin Wang, Yushu Hu, and Renshi Xu. The pathogenic mechanism of tar dna-binding protein 43 (tdp-43) in amyotrophic lateral sclerosis. Neural Regeneration Research, 19:800-806, Sep 2024. URL: https://doi.org/10.4103/1673-5374.382233, doi:10.4103/1673-5374.382233. This article has 29 citations and is from a peer-reviewed journal.

6. (copley2024shortrnachaperones pages 15-17): Katie E. Copley, Jocelyn C. Mauna, Helen Danielson, Marilyn Ngo, Longxin Xie, Ashleigh Smirnov, Matt Davis, Leland Mayne, Miriam Linsenmeier, Jack D. Rubien, Bede Portz, Bo Lim Lee, Hana M. Odeh, Martina Hallegger, Jernej Ule, Piera Pasinelli, Yan Poon, Nicolas L. Fawzi, Ben E. Black, Christopher J. Donnelly, Brigid K. Jensen, and James Shorter. Short rna chaperones promote aggregation-resistant tdp-43 conformers to mitigate neurodegeneration. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.14.628507, doi:10.1101/2024.12.14.628507. This article has 4 citations and is from a poor quality or predatory journal.

7. (lepine2024transcriptomebasedscreeningin pages 49-54): Sarah Lépine, Gilles Maussion, Alexandria Schneider, Angela Nauleau-Javaudin, María José Castellanos-Montiel, Georgina Jiménez Ambriz, Dan Spiegelman, Narges Abdian, Anna Krystina Franco-Flores, Ghazal Haghi, Lale Gursu, Mathilde Chaineau, and Thomas Durcan. Transcriptome-based screening in tardbp/tdp-43 knock-in motor neurons identifies the nedd8-activating enzyme inhibitor mln4924. Scientific Reports, Dec 2024. URL: https://doi.org/10.21203/rs.3.rs-5404388/v1, doi:10.21203/rs.3.rs-5404388/v1. This article has 1 citations and is from a peer-reviewed journal.

8. (lepine2024theeffectsof pages 49-54): S Lépine. The effects of tardbp mutations associated with amyotrophic lateral sclerosis in human motor neurons derived from induced pluripotent stem cells. Unknown journal, 2024.

## Citations

1. wang2024thepathogenicmechanism pages 1-1
2. riemenschneider2024exploringcellulartoxicity pages 24-27
3. copley2024shortrnachaperones pages 15-17
4. lepine2024transcriptomebasedscreeningin pages 49-54
5. part2024exploringtherole pages 26-30
6. casiraghi2024aggregationmechanismsof pages 10-14
7. lepine2024theeffectsof pages 54-58
8. lepine2024theeffectsof pages 49-54
9. https://doi.org/10.4103/1673-5374.382233
10. https://doi.org/10.1126/sciadv.adf6895
11. https://doi.org/10.1101/2024.07.02.601776
12. https://doi.org/10.1101/2024.12.14.628507
13. https://doi.org/10.21203/rs.3.rs-5404388/v1
14. https://doi.org/10.20381/ruor-30175,
15. https://doi.org/10.5282/edoc.34109,
16. https://doi.org/10.4103/1673-5374.382233,
17. https://doi.org/10.1101/2024.12.14.628507,
18. https://doi.org/10.21203/rs.3.rs-5404388/v1,